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Abstract 
Left atrial enlargement (LAE) has adverse prognostic implications in hypertension. 
We sought to determine the accuracy of 5 ECG criteria for LAE in hypertension 
relative to cardiac magnetic resonance (CMR) gold-standard, and investigate the 
effect of concomitant obesity. 130 consecutive patients (age: 51.4 ± 15.1 years, 47% 
male, 51% obese, systolic blood pressure: 171 ± 29mmHg, diastolic blood pressure: 
97 ± 15mmHg) referred for CMR (1.5T) from a tertiary hypertension clinic were 
included. Patients with concomitant cardiac pathology were excluded. ECGs were 
assessed blindly for: 1) P wave >110ms, 2) P mitrale, 3) P wave axis <30°, 4) Area of 
negative P terminal force in V1 >40ms·mm and 5) Positive P terminal force in aVL 
>0.5mm. LA volume ≥55ml/m2, measured blindly by CMR, was defined as LAE. 
Sensitivity, specificity, positive predictive value, negative predictive value, accuracy 
and area under the receiver operator curve were calculated. The prevalence of LAE 
by CMR was 26%. All the individual ECG LAE criteria were more specific than 
sensitive, with specificities ranging from 70% (P axis <30o) to 99% (P mitrale). Obesity 
attenuated the specificity of most of the individual ECG LAE criteria. Obesity 
correlated with significant lower specificity (48% vs 65%, P < 0.05) and a trend 
towards lower sensitivity (59% vs 43%, P = 0.119) when ≥1 ECG LAE criteria were 
present. Individual ECG criteria of LAE in hypertension are specific, but not sensitive, 
at identifying LAE. The ECG should not be used to excluded LAE in hypertension, 
particularly in obese subjects. 
 
 
 
Introduction 
The 2013 joint European Society of Cardiology and European Society of Hypertension 
guidelines for the management of arterial hypertension advise that a 12-lead 
electrocardiogram (ECG) should be acquired for all patients with hypertension(1). 
The ECG can show evidence of left atrial enlargement (LAE), which is an important 
predictor of cardiovascular mortality and morbidity. Indeed, performing an ECG in all 
subjects with hypertension is advised by the American Society of Hypertension and 
International Society of Hypertension (ASH/ISH) in their joint clinical practice 
guidelines, at least in part to assess for LAE(2). LAE has been demonstrated to be a 
marker of left ventricular (LV) diastolic dysfunction(3) and a predictor of the 
development of atrial fibrillation(4), congestive heart failure(5), stroke(6), 
myocardial infarction(7) and cardiac mortality(8). Detecting of LAE is therefore 
important in subjects with hypertension. All subjects with hypertension should have 
an ECG performed. LAE can be demonstrated on ECG. The first line imaging modality 
to structurally assess the heart in hypertension is the echocardiogram and this can 
be used to gauge the left atrial size. To date, LAE ECG criteria have been assessed 
against two-dimensional (2D) echocardiography reference standards(9)(10) (11)(12).  
However, echocardiographic measurements may be inaccurate due to limited 
acoustic windows and variation in image acquisition planes. This may be particularly 
troublesome in obesity subjects, with is a common comorbidity in subjects with 
hypertension. Furthermore, since the left atrium (LA) is not spherical, the 
assumption of a constant radius necessary for the M-mode or some 2D 
echocardiography measurements, e.g. the ellipsoid method, does not hold true, 
limiting the accuracy(13). Cardiac magnetic resonance imaging (CMR) has superior 
spatial resolution compared to echocardiography and can consistently acquire LA 
images regardless of patient body habitus and, for these reasons, CMR is considered 
gold-standard for atrial assessment. Yet, there are few studies investigating the 
diagnostic performance of ECG LAE criteria against CMR. Furthermore, those existing 
studies were either in unselected subjects undergoing CMR and not in the context of 
hypertension(14) or have used an indexed LA volume of >28ml/m2 to define LAE(15), 
which is from the echocardiogram literature(16) and is significantly lower than LA 
volume of 55ml/m2 which is 2 standard deviation measurements above the mean of 
normal, healthy subjects from published CMR studies(17)(18)(19)(20). Thus, to date, 
ECG LAE criteria appear to have been validated against a variety of reference 
standards. As the ECG is often the first diagnostic investigation performed when 
assessing for LAE in hypertensive patients, and treatment decisions may be made on 
its results, understanding the diagnostic performance of the ECG at detecting LAE 
relative to CMR gold-standard in a cohort of hypertensive subjects is important.  
 
Obesity and hypertension are common co-morbidities. The former has also been 
associated with LAE(21). However, to the best of our knowledge, no previous study 
has investigated the impact of obesity on the diagnostic performance of the ECG at 
detecting LAE. Consequently, our aim was to comprehensively evaluate the 
diagnostic performance of 5 ECG criteria for the detection of LAE, in a cohort of 
hypertensive patients with high LAE prevalence, relative to CMR derived 
measurements of LA volume. Additionally, we sought to determine the effect of 
obesity on the diagnostic performance of the ECG at detecting LAE. 
 
 Methods 
Study population 
In our institution, CMR is used routinely in the tertiary hypertension clinic setting to 
detect hypertensive end-organ damage and screen for potential secondary causes of 
hypertension(22). In this prospective study, we included all eligible, consecutive 
hypertensive patients referred for a CMR from the Bristol Heart Institute tertiary 
hypertension clinic, which has a catchment area of the South West of England, 
between January 2011 and February 2015 (Figure 1). Subjects were excluded from 
analysis if they exhibited any concomitant cardiac pathology, which could confound 
the aetiology of LAE, such as previous myocardial infarction, other cardiomyopathy 
and/or moderate-severe valvular heart disease.  
 
Demographic and baseline clinical data were documented. The World Health 
Organization definition of obesity of body mass index (BMI) > 30kg/m2 was used(23).  
The mean office systolic blood pressure (SBP) and diastolic blood pressure (DBP) 
values were from repeated readings from both arms, where available, recorded with 
an appropriately-sized BP cuff at the time of ECG acquisition, following a period of 5 
minutes seated rest. 
 
Subjects provided written consent for their images to be used for research.  
The study conformed to the governance arrangements for research ethics 
committees (REC).  
 
ECG 
A standard 12-lead ECG (scale: 10mm = 1mV, speed: 25 mm/s) was recorded supine, 
during quiet respiration. The analyzing clinician was blinded to all other CMR and 
clinical data. The presence of complete bundle branch block was an exclusion 
criterion. The 5 ECG LAE criteria evaluated were: 1) P wave >110ms, 2) P mitrale 
(notched P wave with inter-peak duration >40ms), 3) P wave axis <30°, 4) Area of 
negative P terminal force in lead V1 (NPTF-V1) > 40ms·mm and 5) Positive P terminal 
force in aVL (PPTF-aVL) >0.5mm(9)(24)(12)(25). 
 
CMR protocol 
CMR was performed with the subjects lying supine at 1.5T (Avanto, Siemens, 
Erlangen, Germany), with anterior 8-element and posterior 8-element body-array 
coils. Steady state free precession (SSFP) cines were acquired (Time to echo 1.07ms, 
temporal resolution 38.1ms, in-plane pixel size 2.0 x 2.0mm, matrix 156 x 192) with 
retrospective ECG-gating and breath-holding. The entire LV was imaged with short 
axis SSFP with slice thickness of 8mm and no slice gap. The standard 3 long-axis cines 
(4-chamber, 2-chamber and 3-chamber) were acquired at 60 degrees from each 
other. Additionally, late gadolinium myocardial enhancement (LGE) imaging was 
routinely acquired using an inversion-recovery fast gradient echo sequence, as well 
as a phase-sensitive inversion-recovery sequence, 10-15 minutes following 
0.1mmol/kg intravenous gadobutrol (Gadovist, Bayer Pharma AG, Germany). 
Inversion times were optimized in each patient to ensure adequate nulling of normal 
myocardium. Subjects with subendocardial LGE consistent with previous MI were 
excluded.  
 CMR analysis 
All CMR analysis was performed blinded to all other clinical and ECG data by an 
experienced CMR reader using dedicated CMR post-processing software (CMR42, 
Circle Cardiovascular Imaging Inc., Calgary, Canada). Maximum left atrial (LA) volume 
was measured at maximal atrial dilatation at left ventricular end-systole, as 
previously described (Figure 2)(14)(26). Briefly, maximum LA volume was defined as 
the image immediately preceding the opening of the mitral valves on SSFP cines. LA 
length was measured at maximum atrial dilatation from the posterior LA wall to the 
level of the mitral valve plane, parallel to the long-axis of the heart, in the 2-chamber 
and 4-chamber SSFP cines. The endocardial board of the LA was manually contoured 
at maximum atrial diastole in the apical 2-chamber and 4-chamber SSFP cines. The 
confluence of the pulmonary veins and LA appendage were excluded from 
planimetry measurements. The left atrial borders were delimited at the planes of the 
AV annulus and the junctions of venous inflow. LA volume was then calculated 
according to the biplane area-length method and then indexed to body surface area 
(BSA)(16)(27)(28), calculated using the Mosteller formula. LAE was defined as 
≥55ml/m2 which is 2 standard deviation measurements above the mean of normal, 
healthy subjects from published CMR studies(17)(18)(19)(20). 
 
LVM was measured as described previously(29)(30). In brief, LV endocardial contours 
were generated on the short axis SSFP cines stack at end-diastole using previously 
validated(31) blood-pool threshold detection software (CMR42, Circle Cardiovascular 
Imaging Inc., Calgary, Canada). Epicardial contours were manually plotted. LVM was 
derived by multiplying total myocardial volume, inclusive of trabeculae and papillary 
muscles, by myocardial specific gravity (1.05 g/ml), as previously described(29). LVM 
was indexed to BSA. Left ventricular hypertrophy (LVH) was defined as LVM/BSA  
>95th percentile of established CMR reference ranges (women = 77-78g/m2 and men 
= 89-93g/m2)(29). 
 
Statistical analysis 
All statistical analyses were performed in SPSS (v.21, Armonk, NY, USA: IBM Corp). 
Using the pooled prevalence of LAE of 32% from a recent systematic review of 
10,141 subjects assessed by echocardiogram(32), an alpha error of 0.05 and a 
statistical power of 90%, the sample size for our study, accounting for the fact that 
CMR has been demonstrated to reduce the sample sizes by 6-fold compared to 2D 
echocardiogram when a power of 90% is employed(33), should be 100. 
Consequently, our final sample size of 130 subjects, from an initial 160 subjects who 
were screened, was sufficient for this study. Normally-distributed continuous 
variables were expressed as mean ± standard deviation and compared using 
unpaired Student’s T test or one-way analysis of variance with post-hoc correction 
for multiple testing as appropriate. Categorical variables were expressed as 
percentages and interrogated with the Fisher’s exact test. Specificity, sensitivity, 
negative predictive value (NPV), positive predictive valve (PPV) and accuracy were 
also calculated. Area under the receiver-operating curve (AUC-ROC) analysis was 
performed and to compare the diagnostic performance of the various ECG criteria. R 
values are for Pearson’s correlation coefficient. Multivariate logistic regression 
analysis was performed to identify independent predictors of ECG false positives and 
false negatives of LAE relative to CMR. Statistical significant was set at P < 0.05. 
 
Results 
Demographics 
One hundred and sixty consecutive patients referred for CMR were assessed for 
eligibility. Thirty patients met the exclusion criteria (Figure 1), resulting in a final 
sample size of 130 (men: 47%, age: 51 ± 15 years). CMR evidence of LAE was present 
in 26% (n = 34) and obesity was present in 51% (n = 67) of the cohort. There were no 
significant differences between non -obese and obese cohorts for the following 
variables: age, gender, office SBP, office DBP, treatment with angiotensin converting 
enzyme inhibitor / angiotensin II receptor blocker or calcium channel blocker (Table 
1).  
 
Diagnostic performance of ECG criteria of LAE 
Specificity was higher than sensitivity for all ECG LAE criteria (Table 2). Specificities 
ranged from 70% to 99% for the individual ECG criteria of LAE. However, the 
sensitivities ranged from 0% to 18% and the best performance on AUC-ROC was 
0.502 (95th CI: 0.389 – 0.616) for PPTF-aVL > 0.5 mm. A composite ECG criterion 
consisting of any positive individual ECG criteria for LAE had the highest sensitivity of 
29% but a specificity of 48% and accuracy of 43%. 
 
Obesity subgroup analysis of diagnostic performance of ECG criteria for LAE 
The specificity was significantly lower in obese subjects compared to non-obese 
subjects for P wave < 30o (non-obese: 83% vs obese: 64%, P < 0.05) and for the 
composite ECG criterion consisting of any positive individual ECG criteria (non-obese: 
65% vs obese: 48%, P < 0.05) (Table 3). There were non-significant trends for lower 
specificity for NPTF-V1 > 40 ms.mm (non-obese: 89% vs obese: 78%, P = 0.06) and 
PPTF-aVL > 0.5 mm (non-obese: 96% vs obese: 88%, P = 0.07) for obese compared to 
non-obese subjects. 
 
The AUC-ROC values were lower for all ECG criteria of LAE and for the composite 
ECG criterion consisting of any positive individual ECG criteria for obese subjects 
compared to non-obese subjects (Table 3). 
 
Indexed LA size in subjects with positive ECG criteria  
The mean indexed LAV were not significantly different between those subjects with 
positive ECGs compared to negative ECGs for all the ECG criteria for LAE investigated 
(Table 4). There was no correlation between the number of positive ECG criteria and 
absolute LAV (R = -0.05, P = 0.66) or index LAV (R = -0.09, P = 0.4). However, in 
obesity subgroup analysis, there were consistent trends towards larger absolute and 
indexed LAV in obese subjects who did not fulfill ECG criteria for LAE compared to 
obese subjects who did fulfill ECG criteria for LAE. In addition, obese subjects who 
did not fulfill ECG criteria for LAE had significantly large absolute LAV compared to 
similar non-obese subjects but these significant differences no longer persisted after 
indexing the LAV to BSA. 
 
Prevalence of LAE in subjects without hypertensive left ventricular hypertrophy  
Of the 130 hypertensive subjects, 35% (46/130) had LVH and 65% (84/130) did not 
have LVH. LAE occurred in 19% (16/84) of subjects without LVH. However, the 
prevalence of LAE amongst subjects with LVH (39%, 18/46) was significantly higher 
than amongst subjects without LVH (LAE and LVH: 39% vs LAE and no LVH: 19%, P < 
0.05).  
 
Predictors of false positive ECG criteria for LAE 
Multivariate logistic regression analyses, accounting for age, gender and BMI, were 
performed to identify predictors of false positive and false negative ECGs for LAE 
(Table 5). For P wave axis < 30o, female gender and increasing BMI were significant 
independent predictors of false positive ECGs for LAE relative to CMR gold-standard. 
Age, gender and BMI were not predictors of false negative ECGs for LAE. 
 
 
Discussion 
For the first time, we investigate the impact of obesity on the diagnostic 
performance of the ECG at detecting LAE as compared to CMR gold-standard in 
subjects with arterial hypertension.  
 
We demonstrate that all the ECG criteria for LAE are poor at excluding LAE relative to 
CMR. Consequently, a normal ECG in a hypertensive patient has a high chance of 
being falsely reassuring for an absence of LAE, and is less specific for LAE in the 
presence of obesity. LAE is a marker of left ventricular (LV) diastolic dysfunction(3) 
and a predictor for the development of atrial fibrillation(4), congestive heart 
failure(5), stroke(6), myocardial infarction(7) and cardiac mortality(8). Failing to 
identify LAE may alter an individual’s cardiovascular risk estimation and theoretically 
could have treatment implications(1). Furthermore, in subgroup analysis of the LIFE 
study, Wachtell et al. found that prevention of AF during antihypertensive treatment 
may be improved by antihypertensive therapy that reduces LA size in addition to 
controlling blood pressure(34) and the effect of different antihypertensive agents on 
LA size has been previously been investigated(35). 
 
The sensitivity of the ECG at excluding LAE has varied from 6 to 69% relative to 
echocardiography in previous studies(9)(10)(11)(12)(36). Regarding individual ECG 
criteria, we found higher sensitivity for P wave >110ms compared to previous 
echocardiographic studies(9)(10)(12)(25). We demonstrate higher sensitivity for P 
mitrale and NPTF-V1 > 40ms·mm compared to the most recent echocardiographic 
study of 261 randomly selected patients, which calculated LAV using a similar bi-
plane atrial volume analysis from 2-dimensional echocardiography(36). Our findings 
are similar to those of Tsao et al. who performed ECG-CMR correlation, albeit in 
unselected patients(14). 
 
However, it should be realized that a direct comparison between existing 
echocardiography studies and our work is prone to discrepancy. Estimation of atrial 
size with echocardiography, both by M-mode and 2-dimensional techniques, may be 
limited by poor acoustic windows and limited spatial resolution, which may 
underestimate left atrial dimensions. Indeed, the atrial size measured by CMR 
measurement are recognized to exceed echocardiograph measurements of LAV by 
14-37%(37)(38). As a result, the thresholds and accuracy for defining LAE will differ 
between studies using CMR and echocardiography as the gold-standard for LAV and, 
therefore, the proportion of individuals classified as having LAE will also differ which 
will impact on sensitivity and specificity analyses. Furthermore, differing allometric 
scaling of LAV between studies may be another important variable.  
 
Whilst the ECG criteria generally have a high specificity for identifying LAE, we show 
for the first time that the diagnostic performance falls in the presence of obesity.  
This is potentially an important finding with clinical implications. The MONIC/KORA 
(monitoring of trends and determinations in cardiovascular disease/cooperative 
research in the region of Augsburg) study of 1,212 participants demonstrated that 
whilst both hypertension and obesity were predictors of LAE, obesity was 
numerically stronger(39). Furthermore, obesity hypertensive subjects had the largest 
indexed LAV(39). The lower specificity of the ECG at identifying LAE relative to CMR 
in our study in obese subjects to non-obese subjects means that the ECG risks 
missing LAE in subjects are at a particular high risk for LAE. A putative reason why 
the ECG is less able to detect enlarged atria in obese subjects is due to electrical 
insulating effects of excess subcutaneous adipose tissue, a phenomenon which has 
previously been postulated to explain the effect of obesity on reducing the 
diagnostic performs of the ECG at detecting left ventricular hypertrophy(40)(41). 
Imaging obese hypertensive subjects with echocardiography to establish a diagnosis 
of LAE may also be difficult because adipose tissue can attenuate the ultrasonic 
beam and reduce the diagnostic quality of the study. 
 In terms of the clinical implications of our study, we suggest that the ECG should still 
remain the initial investigation of choice for assessing for LAE as advised in 
International guidelines(1)(2). However, clinicians should take into account the 
patient’s BMI when interrogating the ECG for LAE. For example, we show that the 
positive predictive value is significantly lower in obese hypertensive subjects 
compared to non-obese subjects for P axis < 30o and PPTF-aVL > 0.5mm. The 
sensitivity of the investigation is also poor for both obese and non-obese subjects. It 
is clearly not practicable to perform CMR in all subjects with hypertension. Clinicians 
should consider investigating hypertensive patients with an additional modality, such 
as echocardiography in the first instance, to confirm the presence of LAE in obese 
subjects with positive P axis < 30o and PPTF-aVL > 0.5mm criteria and in subjects 
where exclusion of LAE is important and may have therapeutic implications, for 
example in subjects with no other evidence of end-target damage where the 
demonstration of LAE would alter the cardiovascular risk sufficiently to alter 
treatment(1). 
 
Finally, it is important to recognize that abnormalities in atrial conduction, and hence 
the electric sign recorded from the atria on the ECG in the form of the P wave can be 
independent of atrial size(42)(43). Multiple aetiologies may manifest with similar P 
wave abnormalities on ECG. As a result, in unselected populations, the ECG is 
unlikely to have good specificity for LAE as the changes may simply represent atrial 
abnormality rather than enlargement.  
 
Limitations 
Our clinical cohort study had a modest sample size of 130 patients. However, the 
increased accuracy and reproducibility of CMR relative to echocardiography 
increases the statistical power of the study. Furthermore, our study was in a selected 
population of well-characterised hypertensive subjects, and excluded patients with 
other concomitant cardiac pathology. Consequently, our results are more applicable 
to the hypertension community than most of the previous studies that have been in 
unselected populations.  
 
We do not routinely estimate total body fat mass in our clinical practice and this 
variable could not be investigated. BMI has been used as a routinely recorded clinical 
surrogate. Theoretically, an increase in lean muscle mass could yield a BMI value in 
the obesity range but this is unlikely to have occurred in our cohort of patients.  
 
In this non-invasive study, we were unable to adjust for certain variables that may 
alter P wave morphology, e.g. atrial pressure(43). The diagnostic accuracy of the ECG 
at detecting left ventricular hypertrophy in hypertension was not investigated in this 
study, but has been recently described(30). 
 
Conclusion 
We have recalibrated 5 ECG criteria for LAE against current non-invasive gold-
standard CMR. The individual ECG criteria are more specific than sensitive at 
identifying anatomical LAE relative to CMR. However, the concomitant presence of 
obesity reduces the specificity for most ECG criteria for LAE. Clinicians need to be 
aware of these differences when interpreting the ESC/ESH and ASH/ISH guidelines 
and tailor the ECG criteria they use accordingly taking into account the patient’s BMI. 
Whilst the ECG may identify LAE, it has poor sensitivity and therefore the ECG should 
not be used in isolation to exclude LAE where this could have treatment implications. 
Obese hypertensive subjects are at risk of false positive and false negative results if 
the ECG is used to screen of LAE. 
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Summary Table 
  
What is known about the topic 
 1) Detecting LAE in hypertension has prognostic and treatment implications. 
 2) The ECG can detect LAE and it has been validated against echocardiographic assessment of LA size. 
 3) The impact of obesity on the ECG detection of LAE has not previously been investigated. 
 
What this study adds 
 1) We recalibrate 5 ECG criteria for LAE against non-invasive gold-standard CMR. 
 2) We show the ECG is more specific than sensitive at detecting LAE and that obesity reduces ECG 
specificity at detecting LAE. 
 3) We identify predictors of false positive and false negative ECG results with multivariate logistic 
regression analysis.  
 4) In hypertension, the ECG should not be used to exclude LAE 
 
LAE = left atrial enlargement. ECG = electrocardiograph. LA = left atrial M = left ventricular mass. CMR = cardiac 
magnetic resonance. 
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Figure legends 
Figure 1. A flow chart demonstrating the study exclusion criteria and final sample 
size (n = 130). *Image artifact from implantable loop recorder device precluding 
volumetric assessment from LV short axis SSFP cine stack. CMR = cardiac magnetic 
resonance, MI = myocardial infarction (defined as subendocardial late gadolinium 
enhancement on CMR), HOCM = hypertrophic obstructive cardiomyopathy (clinical 
and/or CMR diagnosis), LVNC = left ventricular non-compaction cardiomyopathy 
(CMR diagnosis), DCM = idiopathic dilated cardiomyopathy (CMR diagnosis), Mod AR 
= moderate aortic regurgitation, AVR = aortic valve replacement. 
 
Figure 2. Cardiac magnetic resonance measurements from steady state free 
precession cine images of the maximal left atrial area (A1) and the length of LA (L1) 
on 4C-cine (A) and area (A2) and length (L2) on 2C-cine (B). Left atrial 
volume=8/3π[(A1)(A2)/L, where L is the shortest of either L1 or L2. 
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Table 1. Demographic, ECG and left atrial data for all subjects and obesity subgroups 
 
 
    All (n = 130)  Non-obese (n = 63) Obese (n = 67) P-value 
Demographic 
Age (year)   51 ± 15  51 ± 17  52 ± 14  = 0.76 
Gender (% male)  47   52   42   = 0.23 
BMI (kg/m2)    31 ± 6   27 ± 3   35 ± 5    < 0.0001 * 
Office SBP (mmHg)  171 ± 29  173 ± 29  170 ± 30  = 0.57 
Office DBP (mmHg)  97 ± 15  98 ± 16  97 ± 14  = 0.73 
ESH/ESC BP Grade 1 (%) 20   21   19   = 0.86 
ESH/ESC BP Grade 2 (%) 22   22   21   = 0.86 
ESH/ESC BP Grade 3 (%) 41   41   40   = 0.91 
ACEi / ARB (%)   75   73   76   = 0.69 
CCB (%)   53   51   55   = 0.62 
 
ECG data  
P > 110ms (%)   9   10   9   = 0.91 
P mitrale (%)   1   2   0   = 0.30 
P wave axis < 30o (%)   27   21   33   = 0.12 
NPTF-V1 >40ms.mm (%) 17   11   22   = 0.09 
PPTF-aVL >0.5mm (%)  9   6   10   = 0.41 
Any ECG LAE criteria (%) 46   41   51   = 0.28 
 
Left atrial size data 
Absolute LA volume (ml) 99 ± 33  93 ± 28  105 ± 14  < 0.05 * 
Indexed LA volume (ml/m2) 49 ± 15  49 ± 14  48 ± 16  = 0.90 
LAE (%)   26   27   25   = 0.84 
 
BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, ESH / ESC = European 
society of hypertension / European society of cardiology, ACEi = ACE inhibitor, ARB = angiotensin II receptor 
blocker, CCB = calcium channel blocker, LA = left atrial, LAE = left atrial enlargement 
 
  
Table 2. Diagnostic performance of the various ECG parameters at detecting left atrial enlargement. (LAE = left atrial enlargement, ROC-AUC = receiver operator 
curve-area under curve, CI = confidence interval, PPV = positive predictive value, NPV = negative predictive values, ACC = accuracy) 
 
Prevalence  ROC-AUC     Sensitivity  Specificity PPV   NPV   ACC  
ECG LAE (%)  (95th CI)    (%)  (%)  (%)  (%)  (%) 
 
P > 110 ms   9   0.497 (0.384 – 0.610)   9  91  25  74  69 
 
P mitrale   1   0.495 (0.382 – 0.608)   0  99  0  74  73 
 
P axis < 30o   27   0.437 (0.328 – 0.546)   18  70  17  71  56 
 
NPTF-V1 > 40 ms.mm  17   0.465 (0.355 – 0.576)   12  81  18  72  63 
 
PPTF-aVL > 0.5 mm  8   0.502 (0.389 – 0.616)   9  92  27  74  70 
 
Any ECG criteria for LAE 46   0.387 (0.279 – 0.495)   29  48  17  65  43 
 
  
Table 3. Obesity subgroup analysis of diagnostic performance of the various ECG parameters at detecting left atrial enlargement. (LAE = left atrial enlargement, 
ROC-AUC = receiver operator curve-area under curve, CI = confidence interval, PPV = positive predictive value, NPV = negative predictive values, ACC = accuracy) 
 
Prevalence  ROC-AUC     Sensitivity  Specificity PPV   NPV   ACC  
ECG LAE (%)  (95th CI)    (%)  (%)  (%)  (%)  (%) 
 
P > 110 ms    
Non-obese  10   0.515 (0.352 – 0.679)   12  91  33  74  70 
 Obese   9   0.519 (0.357 – 0.681)   12  92  33  75  72 
 
P mitrale  
Non-obese  2   0.529 (0.364 – 0.695)   0  98  0  74  73 
 Obese   0   0.500 (0.340 – 0.660)   0  100  0  75  75 
 
P axis < 30o  
Non-obese  21   0.560 (0.395 – 0.725)   29  83 *  38 *  76  68 
 Obese   34   0.467 (0.309 – 0.625)   29  64  22  73  55 
 
NPTF-V1 > 40 ms.mm   
Non-obese  11   0.504 (0.342 – 0.667)   12  89  29  73  68 
 Obese   21   0.478 (0.320 – 0.636)   18  78  21  74  63 
 
PPTF-aVL > 0.5 mm   
Non-obese  6   0.537 (0.371 – 0.703)   12  96  50 *  75  73 
 Obese   10   0.469 (0.314 – 0.625)   6  88  14  73  67 
 
Any ECG criteria for LAE  
Non-obese  41   0.620 (0.462 – 0.778)   59  65 *  38 *  81  63 * 
 Obese   51   0.475 (0.315 – 0.635)   47  48  24  73  48 
 
* Non-obese vs Obese, P < 0.05 
Table 4: Absolute and index left atrial volume in all subjects, non-obese subjects and obese subjects with positive and negative ECG criteria for LAE. (+ve = 
positive, -ve = negative, LAV = left atrial volume) 
 
 
    All (n = 130)      Non-obese (n = 63)   Obese (n = 67) 
(+ve) ECG (-ve) ECG P-value  (+ve) ECG (-ve) ECG (+ve) ECG (-ve) ECG P-value 
P wave > 110ms (n)  12  118     6  57  6  61 
 LAV (ml)  96 ± 33 99 ± 33 = 0.70   92 ± 30 93 ± 28 99 ± 39 106 ± 36 < 0.05 * 
 Index LAV (ml/m2) 46 ± 15 49 ± 15 = 0.60   49 ± 16  49 ± 14 44 ± 14 49 ± 16 = 0.89 
 
P mitrale (n)   1  129     1  62  0  67 
 LAV (ml)  94  99 ± 33 = 0.89   94  93 ± 28 …  105 ± 36 < 0.05 * 
 Index LAV (ml/m2) 52  49 ± 15 = 0.82   52   49 ± 14 ….  48 ± 16 = 0.97 
 
P wave axis < 30o (n)  35  95     13  50  22  45 
 LAV (ml)  99 ± 31 99 ± 34 = 0.98   98 ± 33 91 ± 27 99 ± 30 108 ± 39 < 0.05 * 
 Index LAV (ml/m2) 48 ± 16 49 ± 15 = 0.74   51 ± 17 48 ± 13 46 ± 15 50 ± 16  = 0.72 
 
NPTF-V1 > 40ms.mm (n) 22  108     7  56  15  52 
 LAV (ml)  94 ± 32 100 ± 33 = 0.43   87 ± 8  93 ± 30 97 ± 38 107 ± 36 < 0.05 * 
 Index LAV (ml/m2) 46 ± 14 49 ± 15 = 0.32   48 ± 8   49 ± 15 45 ± 16 50 ± 15 = 0.74 
 
PPTF-aVL > 0.5 mm (n) 11  119     4  59  7  60 
 LAV (ml)  92 ± 32 100 ± 33 = 0.46   90 ± 29 93 ± 28 93 ± 36 106 ± 36 < 0.05 * 
 Index LAV (ml/m2) 45 ± 16 49 ± 15 = 0.37   48 ± 18 49 ± 14 43 ± 16 49 ± 16 = 0.78 
 
 
* Obese (–ve) ECG vs Non-obsese (–ve) ECG P < 0.05 
Table 5: Multivariate predictors of false positive and false negative ECGs for left atrial enlargement. (ECG = electrocardiogram, LAE = left atrial 
enlargement, CI = confidence interval, BMI = body mass index) 
 
 
Predictors of false positive ECG for LAE  Predictors of false negative ECG for LAE 
    β-coefficient (95% CI)  P-value  β-coefficient 95% CI  P-value 
P wave >110ms   
 Age (years)  1.03 (0.98 – 1.08)  = 0.23   1.00 (0.90 – 1.11)  = 0.99 
 Male gender  1.78 (0.41 – 7.64)  = 0.44   0.34 (0.02 – 5.83)  = 0.46 
 BMI (kg/m2)  1.02 (0.90 – 1.15)  = 0.80   0.78 (0.57 – 1.07)  = 0.12 
P wave axis <30°  
 Age (years)  1.03 (1.00 – 1.07)  = 0.05   1.02 (0.95 – 1.08)  = 0.66 
 Male gender  0.25 (0.09 – 0.67)  < 0.01 *  2.23 (0.32 – 15.76)  = 0.42 
 BMI (kg/m2)  1.11 (1.02 – 1.21)  < 0.05 *  1.02 (0.47 – 1.24)  = 0.82 
NPTF-V1 > 40ms·mm  
 Age (years)  1.00 (0.97 – 1.03)  = 0.89   0.99 (0.90 – 1.09)  = 0.82 
 Male gender  2.67 (0.86 – 8.25)  = 0.09   0.18 (0.01 – 2.81)  = 0.22 
 BMI (kg/m2)  1.02 (0.93 – 1.11)  = 0.68   0.78 (0.59 – 1.05)  = 0.10 
PPTF-aVL >0.5mm  
 Age (years)  0.98 (0.93 – 1.03)  = 0.49   1.02 (0.93 – 1.11)  = 0.75 
 Male gender  0.24 (0.04 – 1.33)  = 0.10   2.23 (0.16 – 31.33)  = 0.55 
 BMI (kg/m2)  1.05 (0.92 – 1.19)  = 0.31   0.89 (0.70 – 1.14)  = 0.36 
 
